Last reviewed · How we verify
NCT02822027
Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity
NA trial testing human gamma globulin in Preterm Infants in 20 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 June 2016 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- human gamma globulin — full drug profile →
- non-human gamma globulin — full drug profile →
Conditions studied
- Preterm Infants — all drugs for Preterm Infants →
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Who can join
Under 6 Hours, any sex, with Preterm Infants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Infection and inflammation is related to increased encephalopathy of prematurities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02822027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preterm Infants
Currently open trials in the same condition.
- NCT07522892 — Physiological Safety and Behavioral Comfort of Swaddle Bathing in Preterm Infants · NA · recruiting
- NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
- NCT06092463 — The Intestinal Innate Immune System in Newborns. Development and Inflammation in Health and Disease · recruiting
Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials
Trials by the same sponsor.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
- NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
- NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
- NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02822027 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Last refreshed: 14 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02822027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing